JG

Jennifer Griffin

Partner, Strategy & Investor Relations at Mission BioCapital

United States

Invests in

Stages:

Sectors:

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Partner, Strategy & Investor Relations

    2021

  • Board Observer

    2021 - 2021

2020 - 2021

  • Board Observer

    2020 - 2021

  • VP, Industry Strategy & Investments

    2017 - 2021

    The Massachusetts Life Sciences Center (MLSC) is a quasi-state agency that supports life sciences innovation, education, research & development, and commercialization. The MLSC is charged with deploying a $1.6 billion, state-funded investment initiative. Responsible for developing and executing the Commonwealth's overall investment strategy with a focus on supporting early stage companies, recruiting and retaining companies of all stages and talent, and diversifying our industry. Created and managed the $2M Seed Fund, $2M+ public-private partnership MassNextGen to support women entrepreneurs, and other investment programs for early-stage companies. Developed and managed the strategy and execution of the business development efforts that recruit and retain life science companies in the Commonwealth of Massachusetts. Oversaw $40M+ annually in the newly overhauled Capital Programs in order to drive industry partnerships with academia that target specific industry gaps. Developed $10M+ in new Women's Health-focused investment to drive innovation and industry partnership in the space.

2018 - 2021

  • Board Obserer

    2018 - 2021

  • Senior Consultant

    2016 - 2017

  • Consultant

    2015 - 2016

    Advised companies from venture-backed to large pharma and med device on broad commercial topics including product positioning and commercial opportunity, exit strategies, business unit and corporate growth strategies, R&D prioritization, life-cycle management, and asset and company diligence.

2011 - 2014

  • Associate Licensing Officer

    2013 - 2014

    Managed all aspects of commercializing MIT life science technologies including technology assessment, patent prosecution, sourcing opportunities, license structuring and negotiation, license compliance and alliance management.

  • Technology Licensing Associate

    2011 - 2013

    Supported all efforts of licensing and commercializing MIT life science technologies.

2005 - 2011

  • Licensing Intern, Office of Technology Management

    2010 - 2011

    Evaluation of early stage life science technologies including patentability and commercial viability. Developed succinct, accurate and persuasive targeted marketing material for early stage life science technologies with a focus on RNAi therapeutics and delivery technologies.

  • Ph.D. Candidate

    2005 - 2011

    Dept. of Molecular Genetics and Microbiology Lab of Dr. Christopher Sassetti Howard Hughes Medical Investigator Investigated the role of cholesterol in Mycobacterium tuberculosis pathogenesis using transposon mutagenesis and next generation sequencing technology.